VDI
ABCL icon

Vaughan David Investments’s AbCellera Biologics ABCL Stock Holding History

Vaughan David Investments’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78K Hold
10,000
– – ﹤0.01% 244
2026
Q1 		$35K Buy
+10,000
New +$36K ﹤0.01% 234

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Vaughan David Investments's ABCL Position: Q2 2026 in Review

Vaughan David Investments held its AbCellera Biologics (ABCL) position steady in Q2 2026 at 10,000 shares worth $78K. The position accounts for ﹤0.01% of the portfolio, ranked #244.

Vaughan David Investments first reported a position in ABCL in Q1 2026 and has held it in 2 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Vaughan David Investments held 10,000 shares of AbCellera Biologics worth $78K as of Q2 2026.
  • Vaughan David Investments left its AbCellera Biologics share count unchanged in Q2 2026.
  • AbCellera Biologics made up ﹤0.01% of Vaughan David Investments's portfolio in Q2 2026, its #244 holding.
  • Vaughan David Investments first reported a position in AbCellera Biologics in Q1 2026 and has held it in 2 quarters since.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Vaughan David Investments's 13F filing for Q2 2026, filed 11 Aug 2026.